drugset / Trial / NCT01234298
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.
Timeline
- Start
- 2012-01-27
- Primary completion
- 2014-02-24
- Completion
- 2014-02-24
Outcome
Outcome not reported
Stopped (Business): “Study was discontinued due to non-safety related business prioritization decisions”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 20 mg | — |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 30 mg | — |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 40 mg | — |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 50 mg | — |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 60 mg | — |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 70 mg | — |
Indications
No indication recorded.